- Home
- RVMD vs NTRS Comparison
RVMD vs NTRS Comparison
Compare RVMD & NTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RVMD | NTRS |
|---|---|---|
| Founded | 2014 | 1889 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.1B | 32.6B |
| IPO Year | 2020 | 2007 |
Fundamental Metrics
Financial Performance| Metric | RVMD | NTRS |
|---|---|---|
| Price | $203.94 | $188.35 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 19 | 12 |
| Target Price | $140.84 | ★ $163.55 |
| AVG Volume (30 Days) | ★ 1.6M | 812.9K |
| Earning Date | 05-06-2026 | 04-21-2026 |
| Dividend Yield | N/A | ★ 1.94% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 2.71 |
| Revenue | N/A | ★ $8,086,400,000.00 |
| Revenue This Year | N/A | $8.40 |
| Revenue Next Year | $533.02 | $4.13 |
| P/E Ratio | ★ N/A | $68.15 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $42.18 | $121.12 |
| 52 Week High | $224.31 | $195.78 |
Technical Indicators
Market Signals| Indicator | RVMD | NTRS |
|---|---|---|
| Relative Strength Index (RSI) | 47.42 | 53.82 |
| Support Level | $198.91 | $182.41 |
| Resistance Level | $222.33 | $190.18 |
| Average True Range (ATR) | 8.08 | 3.22 |
| MACD | -1.85 | -0.28 |
| Stochastic Oscillator | 15.73 | 75.80 |
Price Performance
Historical ComparisonAbout RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
About NTRS Northern Trust Corporation
Northern Trust is a leading provider of wealth management, asset servicing, asset management, and banking to corporations, institutions, affluent families, and individuals. Founded in Chicago in 1889, Northern Trust has offices in 20 states and Washington, D.C. as well as 23 locations in Canada, Europe, the Middle East, and Asia-Pacific. As of December 2025, Northern Trust had assets under custody or administration of $18.7 trillion and assets under management of $1.8 trillion.